Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
78 participants
INTERVENTIONAL
2023-11-15
2028-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gene Therapy for Diabetic Macular Edema
NCT05916391
A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects with DME
NCT06708260
A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients
NCT06237777
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
NCT03666923
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）
NCT06908876
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FT003 Dose 1
Low dose of FT-003
FT-003
Administered via intraocular injection.
FT003 Dose 2
Mid dose of FT-003
FT-003
Administered via intraocular injection.
FT003 Dose 3
High dose of FT-003
FT-003
Administered via intraocular injection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FT-003
Administered via intraocular injection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female or male patients 18-74 years old at the time of signing the ICF;
* Clinically diagnosed with CI-DME;
* The best corrected visual acuity (BCVA) of the studied eye is 24-73 letters;
Exclusion Criteria
18 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Frontera Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaorong Li, Professor
Role: PRINCIPAL_INVESTIGATOR
Tianjin Medical University Eye Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tianjin Medical University Eye Hospital
Tianjin, Tianjin,China, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xiaorong Li, Professor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FT003-CD101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.